GramEye Inc. CEO Yu Hiraoka Speaks as Panelist at International Symposium "STS forum Japan – Thailand Symposium 2026"

Key facts

  • GramEye Inc. CEO Yu Hiraoka Speaks as Panelist at International Symposium "STS forum Japan – Thailand Symposium 2026"
  • GramEye Inc. CEO Yu Hiraoka participated as a panelist at the international symposium "STS forum Japan – Thailand Symposium 2026" held in Bangkok, Thailand, where he introduced the company's efforts to solve the Antimicrobial Resistance (AMR) problem using AI and robotics technology, and their medical device "Micrium®."
  • Source: PR Times
  • Date: May 7, 2026

Direct answer

GramEye Inc. CEO Yu Hiraoka participated as a panelist at the international symposium "STS forum Japan – Thailand Symposium 2026" held in Bangkok, Thailand, where he introduced the company's efforts to solve the Antimicrobial Resistance (AMR) problem using AI and robotics technology, and their medical device "Micrium®."

Citation
GramEye Inc. CEO Yu Hiraoka Speaks as Panelist at International Symposium "STS forum Japan – Thailand Symposium 2026" (May 7, 2026), PR Times
Source
PR Times
Date
May 7, 2026
GramEye Inc. CEO Yu Hiraoka participated as a panelist at the international symposium "STS forum Japan – Thailand Symposium 2026" held in Bangkok, Thailand, where he introduced the company's efforts to solve the Antimicrobial Resistance (AMR) problem using AI and robotics technology, and their medical device "Micrium®."
イベントNQ 88/100出典:PR Times

📋 Article Processing Timeline

  • 📰 Published: May 7, 2026 at 23:10
  • 🔍 Collected: May 7, 2026 at 14:31
  • 🤖 AI Analyzed: May 7, 2026 at 15:38 (1h 6m after Collected)
GramEye Inc. (Headquarters: Ibaraki City, Osaka Prefecture; Representative Director CEO: Yu Hiraoka; hereinafter "GramEye"), a university-launched startup tackling the Antimicrobial Resistance (AMR) problem with AI and robotics technology, announced that its Representative Director CEO, Yu Hiraoka, spoke as a panelist at the international symposium "STS forum Japan – Thailand Symposium 2026," held in Bangkok, Thailand, from April 23-25, 2026.

■ Session Details

Session Name: PANEL DISCUSSION: The Role of Artificial Intelligence in Modern Society

Date: Friday, April 24, 2026, 15:55-17:05

Venue: World Ballroom, Bangkok Convention Centre at CentralWorld, Bangkok, Thailand

Moderator: Dr. Pranpreya Sriwannawit Lundberg (Secretary, Council for Higher Education, Science, Research and Innovation Policy, Thailand)

Photo provided by STS forum

This session discussed the impact and potential of AI technology on modern society from multiple perspectives, including healthcare, energy, and policy.

Hiraoka participated in a panel discussion on "The Role of AI in Modern Society" and presented on the Antimicrobial Resistance (AMR) problem and GramEye's initiatives. AMR is exacerbated by inappropriate antibiotic prescriptions and is predicted to claim 10 million lives annually by 2050. While its death toll and economic losses already surpass those of climate change, investment in countermeasures remains less than 1/300th of climate change efforts. Hiraoka stated, "There is a great opportunity to create solutions." He also shared that his experience researching antibiotic prescription practices in Thai pharmacies during his student days was the origin of GramEye. The medical device born from that research, "Micrium®," automates Gram staining and supports infectious disease diagnosis. It began sales in Japan in January 2025 and is currently implemented in approximately 25 facilities nationwide. He concluded by saying, "AMR cannot be solved by one country alone. I hope this STS forum will be a platform to accelerate global progress."

Photo provided by STS forum

【Panelist List】

Name | Affiliation/Position
---|---
Dr. Fahad Algnear | Director of International Partnerships|King Abdulaziz City for Science and Technology (KACST), Saudi Arabia
Prof. Kenji Suzuki | Director, Biomedical AI Research Unit (BMAI)|Science Tokyo
Dr. Soontaree Songserm | Deputy Director|Big Data Institute (BDI), Thailand
Dr. Yu Hiraoka, MD | Representative Director CEO|GramEye Inc./Graduate School of Medicine, Osaka University
Mr. Norihiko Ishihara | Representative Director CEO|DataSection Inc. (Online participation)

■ About STS forum Japan – Thailand Symposium 2026

Organizers: National Research Council of Thailand (NRCT)・Ministry of Higher Education, Science, Research and Innovation

Co-organizer: Science and Technology in Society forum (STS forum)

Dates: April 23 (Thursday) – 25 (Saturday), 2026

Venue: World Ballroom, Bangkok Convention Centre at CentralWorld, Bangkok, Thailand

Theme: "The Great Convergence: AI-Driven Health, Environment and Bio-Economy"

This symposium is an authoritative international platform for deepening international cooperation in science, technology, and innovation between Japan and Thailand. Leaders from government, academia, and industry worldwide gathered to discuss global issues such as AI, energy transition, smart healthcare, bio-economy, and environmental problems.

■ About GramEye Inc.

GramEye is a deep tech startup from Osaka University with the mission of "aiming for a world where antibiotics are appropriately prescribed in medical settings worldwide." It leverages AI and robotics technology.

FAQ

What are the key facts in this article?

GramEye Inc. CEO Yu Hiraoka participated as a panelist at the international symposium "STS forum Japan – Thailand Symposium 2026" held in Bangkok, Thailand, where he introduced the company's efforts to solve the Antimicrobial Resistance (AMR) problem using AI and robotics technology, and their medical device "Micrium®."

What is the direct answer?

GramEye Inc. CEO Yu Hiraoka participated as a panelist at the international symposium "STS forum Japan – Thailand Symposium 2026" held in Bangkok, Thailand, where he introduced the company's efforts to solve the Antimicrobial Resistance (AMR) problem using AI and robotics technology, and their medical device "Micrium®."

What is the source and date?

PR Times: https://prtimes.jp/main/html/rd/p/000000014.000098814.html | May 7, 2026